title: New antimony(III) bromide complexes with thioamides: synthesis, characterization, and cytostatic properties.
abstract: New antimony(III) bromide complexes with the heterocyclic thioamides, thiourea (TU), 2-mercapto-1-methylimidazole (MMI), 2-mercapto-benzimidazole (MBZIM), 2-mercapto-5-methyl-benzimidazole (MMBZIM), 5-ethoxy-2-mercapto-benzimidazole (EtMBZIM), 2-mercapto-3,4,5,6-tetrahydro-pyrimidine (tHPMT), 2-mercaptopyridine (PYT), 2-mercapto-thiazolidine (MTZD), 3-methyl-2-mercaptobenzothiazole (MMBZT), and 2-mercaptopyrimidine (PMTH) of formulas [SbBr(3)(TU)(2)] (1), [SbBr(3)(MMI)(2)] (2), {[SbBr(2)(MBZIM)(4)](+) [Br](-) H(2)O} (3), {[SbBr(2)(mu(2)-Br)(MMBZIM)(2)](2)} (4), {[SbBr(2)(mu(2)-Br)(EtMBZIM)(2)](2) MeOH} (5), {[SbBr(3)(mu(2)-S-tHPMT)(tHPMT)](n)} (6), {[SbBr(2)(mu(2)-Br)(PYT)(2))(n)} (7), {[SbBr(2)(mu(2)-Br)(MTZD)(2)](n)} (8), [SbBr(3)(MMBZT)(2)] (9), and {[SbBr(5)](2-)[(PMTH(2)(+))(2)]} (10) have been synthesized and characterized by elemental analysis, conductivity measurements, FTIR spectroscopy, FT-Raman spectroscopy, TG-DTA analysis, and X-ray powder diffraction. The crystal structures of 3, 4, 5, 6, 7, 8, and 10 were also determined by X-ray diffraction. In 3, four sulfur atoms from thione ligands and two bromide ions form an octahedral (O(h)) cationic [SbS(4)Br(2)](+) species in which the two bromide anions lie at axial positions. A third bromide counteranion neutralizes the whole complex. 4 and 5 are dimers, whereas 6, 7 and 8 are polymers, built up by monomeric units of square pyramidal (SP) geometry around the metal center, which were formed by two sulfur atoms of thioamide ligands and three bromide ions. Finally, 10 is ionic salt containing 1D polymeric network of {[SbBr(5)](2-)}(n) anions and (-)[(PMTH(2)(+))2] counter cations in the lattice. The complexes showed mostly a moderate cytostatic activity against a variety of tumor cell lines.
authors.affiliation: Section of Inorganic and Analytical Chemistry, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece.
authors.forename: Ibrahim I
authors.initials: II
authors.lastname: Ozturk
authors.forename: Sotiris K
authors.initials: SK
authors.lastname: Hadjikakou
authors.forename: Nick
authors.initials: N
authors.lastname: Hadjiliadis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kourkoumelis
authors.forename: Maciej
authors.initials: M
authors.lastname: Kubicki
authors.forename: Anastasios J
authors.initials: AJ
authors.lastname: Tasiopoulos
authors.forename: Hanadi
authors.initials: H
authors.lastname: Scleiman
authors.forename: Mirela M
authors.initials: MM
authors.lastname: Barsan
authors.forename: Ian S
authors.initials: IS
authors.lastname: Butler
authors.forename: Jan
authors.initials: J
authors.lastname: Balzarini
mesh_terms: D000818:Animals; D000965:Antimony / Q000737:chemistry*; D001965:Bromides / Q000737:chemistry*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003198:Computer Simulation; D018360:Crystallography, X-Ray; D054697:Cytostatic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D013854:Thioamides / Q000737:chemistry*
chemical_list: D001965:Bromides; D054697:Cytostatic Agents; D009942:Organometallic Compounds; D013854:Thioamides; D000965:Antimony